Cellectar Biosciences, Inc.

Listed Company

CLRBCIK 0001279704NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

—

Equity

—

Shares Out

7.99M

Op. Cash Flow

$-23.12M

Business

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company that discovers, develops and seeks to commercialize cancer drugs using a proprietary phospholipid ether drug conjugate (PDC) delivery platform. Its main product candidates are radioconjugate PDCs, including iopofosine I‑131 (beta emitter), CLR 121225 (actinium‑225 alpha emitter) and CLR 121125 (iodine‑125 Auger emitter), alongside preclinical PDCs delivering small molecules, oligonucleotides and peptides. The company’s operations comprise clinical development (adult and pediatric trials), preclinical programs, partnerships and collaborations, and an outsourced manufacturing model. It conducts international clinical trials and supplies finished radiopharmaceuticals through contract manufacturers and collaborative distribution channels to address global oncology markets.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	11	26	27	19	18
General and administrative	11	26	12	10	7
Total operating expenses	23	52	39	29	24
LOSS FROM OPERATIONS	−23	−52	−39	−29	−24
Warrant issuance expense	—	−8	−470,000	—	—
Gain on valuation of warrants	753,707	14	−4	—	—
Interest income	435,100	1	387,147	152,519	2,284
Total other income (expense), net	1	7	−4	152,519	8,918
LOSS BEFORE INCOME TAXES	−22	−45	−43	−29	−24
INCOME TAX PROVISION (BENEFIT)	—	66,000	−60,000	−60,000	—
NET LOSS	−22	−45	−43	−29	−24
NET LOSS PER SHARE - BASIC (In dollars per share)	−8.35	−36.52	−3.5	−4.05	−4.35
NET LOSS PER SHARE - DILUTED (In dollars per share)	−8.35	−41.89	−3.5	−4.05	−4.35
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC (In shares)	3	1	12	7	6
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED (In shares)	3	1	12	7	6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	13	23	10	20	36
Prepaid expenses and other current assets	842,432	961,665	888,225	663,243	867,485
Total current assets	14	24	10	21	37
Property, plant & equipment, net	549,405	757,121	1	418,641	344,491
Operating lease right-of-use asset	360,671	436,874	502,283	560,334	204,644
Other long-term assets	29,780	29,780	29,780	6,214	6,214
TOTAL ASSETS	15	25	12	22	37
Accounts payable and accrued liabilities	4	8	9	5	4
Warrant liability	226,000	2	16	—	—
Lease liability, current	100,189	84,417	58,979	50,847	135,449
Total current liabilities	5	9	25	6	4
Lease liability, net of current portion	309,397	409,586	494,003	552,981	166,292
TOTAL LIABILITIES	5	10	26	6	4
COMMITMENTS AND CONTINGENCIES (Note 10)	—	—	—	—	—
Common stock, $0.00001 par value; 170,000,000 shares authorized; 4,240,129 and 1,535,996 shares issued and outstanding as of December 31, 2025 and 2024, respectively	42	15	207	94	61
Additional paid-in capital	277	261	183	194	183
Accumulated deficit	−269	−247	−203	−179	−151
Total stockholders' equity	9	14	−15	8	33
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	15	25	12	22	37

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	214,000	292,000	192,000	148,000	150,000
Stock-based compensation	2	4	2	1	1
Loss on disposal of assets	—	145,726	—	3,386	2,937
Warrant issuance expense	—	8	470,000	—	—
Change in operating lease right-of-use asset	76,202	65,409	58,051	—	—
Prepaid expenses and other assets	119,233	−73,440	−173,548	204,242	−93,053
Accounts payable and accrued liabilities	−3	−2	4	2	411,717
Lease liability	−84,417	−58,979	−50,846	−144,035	−119,903
Cash used in operating activities	−23	−48	−32	−25	−23
Purchases of property, plant & equipment	−5,880	−104,195	−864,038	−225,971	−141,361
Cash used in investing activities	−5,880	−104,195	−864,038	−225,971	−141,361
Proceeds from exercise of warrants and new warrants, net of issuance costs	7	61	789,642	—	1
Proceeds from issuance of common stock, pre-funded warrants and common warrants, net of issuance costs	6	—	—	—	—
Cash provided by financing activities	13	61	23	10	1
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	−10	14	−10	−16	−21
Conversion of preferred stock to common stock	—	68	13	—	—
Settlement of warrants to equity	738,325	13	3	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro